Thioalbamide inhibits F o F 1 -ATPase in breast cancer cells and reduces tumor proliferation and invasiveness in breast cancer in vivo models.

Overall, our results shed more light on the molecular mechanisms underlying the pharmacological potential of thioamidated peptides, thus reducing the gap that separates this rare class of microbial metabolites from clinical studies, which could validate them as effective tools for cancer treatment.